Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999

Co-trimoxazole Resistance in Clinical Isolates of Stenotrophomonas maltophilia

“…This is similar to betriu et al, (Betriu et al, 2001) study where 62.7% of the isolates were resistant to amikacin. In Milne et al, (2012) study 86% of the isolates were resistant to amikacin.…”

“…The resistance rates to these two drugs varied from study to study. In Betriu et al, (2001) Milne et al, (2012) and Arora et al, (2012) study where 13.7% and 59% of the isolates were resistant to this antibiotic respectively. Other antibiotics live piperacillin/tazobactum and cefaperazone/ sulbactum have shown equivocal resistance patterns allowing their utility in only half of the isolates (Fig.…”

Ecthyma Gangrenosum: A Rare Cutaneous Manifestation Caused byStenotrophomonas maltophiliain a Leukemic Patient

“…Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as the agent of choice for therapy of S. maltophilia infection as it is found to be active against most strains although resistance is increasing. Ticarcillin-clavulanate is noted to have good activity and is suggested as the agent of choice in individuals intolerant of TMP-SMX 8,14,19 .…”

Hospital-acquired pneumonia: coverage and treatment adequacy of current guidelines

“…At the moment trimethoprim-sulphamethoxazole (TMP-SMZ) is the antibiotic of choice for the treatment of S. maltophilia infections with w90% in vitro susceptibility, followed by ticarcillin clavulanate or ceftazidime with 50% susceptibility [26]. Given the relative lack of agents that have significant activity against S. maltophilia, it is not surprising that this pathogen is virtually almost never covered by the Trouillet or ATS treatments.…”